Regulation of death receptors--relevance in cancer therapies.

作者: A DETHONEL , J ERIKSSON

DOI: 10.1016/J.TAAP.2005.03.032

关键词: ApoptosisRegulation of gene expressionCaspaseCancerBiologyCell biologyProgrammed cell deathCancer cellFas receptorTumor necrosis factor alpha

摘要: Apoptosis is an essential non-inflammatory mechanism for cell removal, which occurs during both physiological and pathological conditions. characteristically executed by cysteine proteases, termed caspases. The most specific way to activate the caspases machinery through death receptors (DRs), such as tumor necrosis factor (TNFR), Fas receptor (FasR), TRAIL (TRAIL-R). apoptotic signaling tightly regulated balance of pro-apoptotic anti-apoptotic proteins imbalance between proliferation may cause numerous diseases, including cancers. intensive research past decade has delineated basic mechanisms apoptosis outlined many important molecular underlying regulation apoptosis. There also a better understanding how can be disturbed in human cancer cells. interplay DRs anticancer drugs offered new concepts development highly therapeutical agents. Here we review current different that regulate DR-mediated defects discovered In light this knowledge, promising target-based agents future therapies have been developed.

参考文章(60)
Alex Toker, Signaling through protein kinase C Frontiers in Bioscience. ,vol. 3, pp. d1134- 1147 ,(1998) , 10.2741/A350
Terry H. Landowski, Kenneth H. Shain, Marc M. Oshiro, Ibrahim Buyuksal, Jeffrey S. Painter, William S. Dalton, Myeloma Cells Selected for Resistance to CD95-Mediated Apoptosis Are Not Cross-Resistant to Cytotoxic Drugs: Evidence for Independent Mechanisms of Caspase Activation Blood. ,vol. 94, pp. 265- 274 ,(1999) , 10.1182/BLOOD.V94.1.265.413K37_265_274
Avi Ashkenazi, Wolfgang Wick, Hiroko Ohgaki, Mathias Bähr, Stefan Isenmann, Michael Platten, Michael Weller, Mitsutoshi Nakamura, Paul Kleihues, Wilfried Roth, Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Research. ,vol. 61, pp. 2759- 2765 ,(2001)
Guido Kroemer, John C. Reed, Mitochondrial control of cell death Nature Medicine. ,vol. 6, pp. 513- 519 ,(2000) , 10.1038/74994
Samar Jasser, W. K.Alfred Yung, Amy Berson, Diana Iliev, Carmen Tornos, Gregory Fujii, Gordon B. Mills, Lee Ellis, Marsha Frazier, Lauren A. Langford, Peter A. Steck, Thaylon Davis, Brad Swedlund, Patricia Troncoso, Cheryl Frye, David H.F. Teng, Raphael E. Pollack, Kipp L. Hansen, Rong Hu, Mark A. Pershouse, Jeff Lee, Adel El-Naggar, Robert Bookstein, Kathryn L. Gumpper, Huai Lin, Scan V. Tavtigian, Vickie L. Vinson, Joseph B. Bolen, MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Research. ,vol. 57, pp. 5221- 5225 ,(1997)
Laleh Shayesteh, Yiling Lu, Wen-Lin Kuo, Russell Baldocchi, Tony Godfrey, Colin Collins, Daniel Pinkel, Bethan Powell, Gordon B. Mills, Joe W. Gray, PIK3CA is implicated as an oncogene in ovarian cancer Nature Genetics. ,vol. 21, pp. 99- 102 ,(1999) , 10.1038/5042
Donald W. Nicholson, From bench to clinic with apoptosis-based therapeutic agents Nature. ,vol. 407, pp. 810- 816 ,(2000) , 10.1038/35037747
Laura DeForge, Jeanine Bussiere, Judith A. Fox, Klara Totpal, Sean K. Kelley, David Xie, Louise A. Harris, Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety Journal of Pharmacology and Experimental Therapeutics. ,vol. 299, pp. 31- 38 ,(2001)